The behavioral profile of spice and synthetic cannabinoids in humans

Brain Research Bulletin

Volumn 126, Issue , 2016, Pages 3-7

  Müller, Helge H ^a,b   Kornhuber, Johannes ^a   Sperling, Wolfgang ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF OLDENBURG   (Germany)

Author keywords

Neuropsychiatric side effects; Somatic effects; Spice; Synthetic cannabinoids; Treatment

Indexed keywords

CANNABINOID; STREET DRUG;

DRUG MECHANISM; HUMAN; INTOXICATION; MENTAL DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RESTLESSNESS; REVIEW; SCREENING; SPICE; SUBSTANCE ABUSE; MEDLINE; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; SYNTHESIS;

CANNABINOIDS; HUMANS; PUBMED; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84962619615     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2015.10.013     Document Type: Review

References (77)

1. Acquas, E., et al. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur. J. Pharmacol. 401:2 (2000), 179–185.
2. Auwarter, V., et al. ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?. J. Mass Spectrom. 44:5 (2009), 832–837.
3. Barratt, M.J., et al. Lessons from conducting trans-national internet-mediated participatory research with hidden populations of cannabis cultivators. Int. J. Drug Policy 26:3 (2015), 238–249.
4. Beck, O., et al. Detectability of new psychoactive substances: ‘legal highs’, in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse. Drug Test. Anal. 6:5 (2014), 492–499.
5. Benford, D.M., Caplan, J.P., Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics, 52(3), 2011, 295.
6. Bhanushali, G.K., et al. AKI associated with synthetic cannabinoids: a case series. Clin. J. Am. Soc. Nephrol. 8:4 (2013), 523–526.
7. Bonnet, U., Mahler, H., Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard. Fortschr. Neurol. Psychiatr. 83:4 (2015), 221–231.
8. Brakoulias, V., Products containing synthetic cannabinoids and psychosis. Aust. N. Z. J. Psychiatry 46:3 (2012), 281–282.
9. Brents, L.K., Prather, P.L., The K2/spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab. Rev. 46:1 (2014), 72–85.
10. Buckley, N.E., et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396:2–3 (2000), 141–149.
11. Cox, M.L., Haller, V.L., Welch, S.P., The antinociceptive effect of delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. Eur. J. Pharmacol. 570:1–3 (2007), 50–56.
12. Cui, Y.Y., et al. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. Eur. J. Pharmacol. 573:1–3 (2007), 206–213.
13. Darmani, N.A., Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR. 141716A. Neuropsychopharmacology 24:2 (2001), 198–203.
14. Davies, S., et al. Purchasing ‘legal highs’ on the internet—is there consistency in what you get?. QJM 103:7 (2010), 489–493.
15. Di Forti, M., et al. High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 195:6 (2009), 488–491.
16. Di Forti, M., et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr. Bull. 40:6 (2014), 1509–1517.
17. Durand, D., et al. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin. Schizophr. Relat. Psychoses 8:4 (2015), 205–208.
18. Ernst, L., et al. Identification and characterization of JWH-122 used as new ingredient in spice-like herbal incenses. Forensic Sci. Int. 208:1–3 (2011), e31–5.
19. Fattore, L., Fratta, W., Beyond THC: the new generation of cannabinoid designer drugs. Front. Behav. Neurosci., 5, 2011, 60.
20. Forrester, M.B., Haywood, T., Geographic distribution of synthetic cannabinoid exposures reported to Texas poison centers. Am. J. Drug Alcohol Abuse 38:6 (2012), 603–608.
21. Forrester, M.B., et al. Synthetic cannabinoid exposures reported to Texas poison centers. J. Addict. Dis. 30:4 (2011), 351–358.
22. Forrester, M.B., et al. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum. Exp. Toxicol. 31:10 (2012), 1006–1011.
23. Forrester, M.B., Adolescent synthetic cannabinoid exposures reported to Texas poison centers. Pediatr. Emerg. Care 28:10 (2012), 985–989.
24. Goshgarian, A.M., Benford, D.M., Caplan, J.P., Bath salt abuse: neuropsychiatric effects of cathinone derivatives. Psychosomatics 52:6 (2011), 593–594.
25. Grabenauer, M., et al. Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. Anal. Chem. 84:13 (2012), 5574–5581.
26. Grigoryev, A., et al. Chromatography–mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879:15–16 (2011), 1126–1136.
27. Grigoryev, A., Kavanagh, P., Melnik, A., The detection of the urinary metabolites of 3-[(adamantan-1-yl) carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography–mass spectrometry. Drug Test. Anal. 4:6 (2012), 519–524.
28. Grigoryev, A., Kavanagh, P., Melnik, A., The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl) methanone (AM-694): a high affinity cannabimimetic, by gas chromatography—mass spectrometry. Drug Test. Anal. 5:2 (2013), 110–115.
29. Grotenhermen, F., Pharmacology of cannabinoids. Neuro Endocrinol. Lett. 25:1–2 (2004), 14–23.
30. Grotenhermen, F., Cannabinoids. Curr. Drug Targets CNS Neurol. Disord. 4:5 (2005), 507–530.
31. Gunderson, E.W., et al. Spice and K2 herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am. J. Addict. 21:4 (2012), 320–326.
32. Gunderson, E.W., Synthetic cannabinoids: a new frontier of designer drugs. Ann. Intern. Med. 159:8 (2013), 563–564.
33. Gurdal, F., et al. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey. J. Forensic Leg. Med. 20:6 (2013), 667–672.
34. Hall, W., Degenhardt, L., High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. BMJ, 350, 2015 p. h1205.
35. Harris, C.R., Brown, A., Synthetic cannabinoid intoxication: a case series and review. J. Emerg. Med. 44:2 (2013), 360–366.
36. Hermanns-Clausen, M., et al. Acute intoxication by synthetic cannabinoids—four case reports. Drug Test. Anal. 5:9–10 (2013), 790–794.
37. Hillebrand, J., Olszewski, D., Sedefov, R., Legal highs on the internet. Subst. Use Misuse 45:3 (2010), 330–340.
38. Hoyte, C.O., et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann. Emerg. Med. 60:4 (2012), 435–438.
39. Hudson, S., Ramsey, J., The emergence and analysis of synthetic cannabinoids. Drug Test. Anal. 3:7–8 (2011), 466–478.
40. Hurst, D., Loeffler, G., McLay, R., Psychosis associated with synthetic cannabinoid agonists: a case series. Am. J. Psychiatry, 168(10), 2011, 1119.
41. Jaenicke, N.J., et al. Retrospective analysis of synthetic cannabinoids in serum samples—epidemiology and consumption patterns. Forensic Sci. Int. 242 (2014), 81–87.
42. Jinwala, F.N., Gupta, M., Synthetic cannabis and respiratory depression. J. Child Adolesc. Psychopharmacol. 22:6 (2012), 459–462.
43. Kadaria, D., Sinclair, S.E., A case of acute agitation with a negative urine drug screen: a new wave of legal drugs of abuse. Tenn. Med. 105:9 (2012), 31–32.
44. Kemp, A., et al. Top 10 facts you should know. Synthetic cannabinoids: not so nice spice. J. Miss. State Med. Assoc. 56:5 (2015), 125–127 129–130.
45. Khullar, V., Jain, A., Sattari, M., Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones. J. Gen. Intern. Med. 29:8 (2014), 1200–1204.
46. Latorre, J.G., Schmidt, E.B., Cannabis, cannabinoids, and cerebral metabolism: potential applications in stroke and disorders of the central nervous system. Curr. Cardiol. Rep., 17(9), 2015, 627.
47. Le Foll, B., Tyndale, R.F., Cannabinoids: friend or foe?. Clin. Pharmacol. Ther. 97:6 (2015), 528–531.
48. Liechti, M., Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med. Wkly., 145, 2015, w14043.
49. Marshell, R., et al. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid delta9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol. Biochem. Behav. 124 (2014), 40–47.
50. McGuinness, T.M., Newell, D., Risky recreation: synthetic cannabinoids have dangerous effects. J. Psychosoc. Nurs. Ment. Health Serv. 50:8 (2012), 16–18.
51. Mills, B., Yepes, A., Nugent, K., Synthetic cannabinoids. Am. J. Med. Sci. 350:1 (2015), 59–62.
52. Mobius, C., et al. c-MRI findings after crystal meth abuse. J. Addict. Med. 8:5 (2014), 384–385.
53. Moller, I., et al. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test. Anal. 3:9 (2011), 609–620.
54. Muller, H., et al. Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 43:4 (2010), 152–153.
55. Muller, H., et al. The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr. Res. 118:1–3 (2010), 309–310.
56. Muller-Vahl, K., Grotenhermen, F., Cannabis therapy. Dtsch. Arztebl Int., 110(9), 2013, 144.
57. Musshoff, F., et al. Legal highs from the German internet—bath salt drugs on the rise. Arch. Kriminol. 232:3–4 (2013), 91–103.
58. Mycyk, M.B., Emerging drugs of abuse: what was new yesterday is new today. J. Med. Toxicol. 8:1 (2012), 1–2.
59. Oluwabusi, O.O., et al. Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc. Psychopharmacol. 22:5 (2012), 393–395.
60. Ortega, A., et al. On the effects of cand other cannabinoid receptor agonists in C6 and U373 cell lines. Toxicol. In Vitro, 2015, 55–940.
61. Paul, M., et al. Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC–HR–QTOFMS approach. Anal. Bioanal. Chem. 406:18 (2014), 4425–4441.
62. Penders, T., Saeed, S., Synthetic cannabinoids and bath salts should be considered drugs of abuse. Am. Fam. Physician, 2012, 852.
63. Rech, M.A., et al. New drugs of abuse. Pharmacotherapy 35:2 (2015), 189–197.
64. Rosenbaum, C.D., Carreiro, S.P., Babu, K.M., Here today, gone tomorrow and back again? A review of herbal marijuana alternatives (K2, spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J. Med. Toxicol. 8:1 (2012), 15–32.
65. Sachs, J., McGlade, E., Yurgelun-Todd, D., Safety and toxicology of cannabinoids. Neurotherapeutics, 2015.
66. Seely, K.A., et al. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?. Mol. Interv. 11:1 (2011), 36–51.
67. Seely, K.A., et al. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry 39:2 (2012), 234–243.
68. Soderstrom, K., Tian, Q., CB(1) cannabinoid receptor activation dose dependently modulates neuronal activity within caudal but not rostral song control regions of adult zebra finch telencephalon. Psychopharmacology (Berl.) 199:2 (2008), 265–273.
69. Strano-Rossi, S., et al. Ultra high performance liquid chromatography–electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, spice and stimulants in oral fluid. J. Chromatogr. A 1258 (2012), 37–42.
70. Sundstrom, M., et al. A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC–HR–TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal. Bioanal. Chem. 405:26 (2013), 8463–8474.
71. Torjesen, I., High potency cannabis is associated with tripled risk of psychosis, study indicates. BMJ, 350, 2015 p. h939.
72. Underwood, E., Alarm over synthetic cannabinoids. Science, 347(6221), 2015, 473.
73. van Amsterdam, J., Brunt, T., van den Brink, W., The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J. Psychopharmacol. 29:3 (2015), 254–263.
74. Van der Veer, N., Friday, J., Persistent psychosis following the use of spice. Schizophr. Res. 130:1–3 (2011), 285–286.
75. WHO, Expert Committee on Drug Dependence. Thirty-sixth report. World Health Organ. Tech. Rep. Ser. 991 (2015), 1–50 back cover.
76. Weaver, M.F., Hopper, J.A., Gunderson, E.W., Designer drugs 2015: assessment and management. Addict. Sci. Clin. Pract., 10, 2015, 8.
77. Wiley, J.L., et al. 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend. 123:1–3 (2012), 148–153.